The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Epalrestat: An Aldose Reductase Inhibitor for the Treatment of Diabetic Neuropathy
Abstract
Diabetic neuropathy is one of the most common long‐term complications in patients with diabetes mellitus, with a prevalence of 60–70% in the United States. Treatment options include antidepressants, anticonvulsants, tramadol, and capsaicin. These agents are modestly effective for symptomatic relief, but they do not affect the underlying pathology nor do they slow progression of the disease. Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy. Unlike the current treatment options for diabetic neuropathy, epalrestat may affect or delay progression of the underlying disease process. Data from experimental studies indicate that epalrestat reduces sorbitol accumulation in the sciatic nerve, erythrocytes, and ocular tissues in animals, and in erythrocytes in humans. Data from six clinical trials were evaluated, and it was determined that epalrestat 50 mg 3 times/day may improve motor and sensory nerve conduction velocity and subjective neuropathy symptoms as compared with baseline and placebo. Epalrestat is well tolerated, and the most frequently reported adverse effects include elevations in liver enzyme levels and gastrointestinal‐related events such as nausea and vomiting. Epalrestat may serve as a new therapeutic option to prevent or slow the progression of diabetic neuropathy. Long‐term, comparative studies in diverse patient populations are needed for clinical application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dyck, P. J., Kratz, K. M., Karnes, J. L., Litchy, W. J., Klein, R., Pach, J. M., Wilson, D. M., O'Brien, P. C., & Melton, L. J. (1993) · Neurology · doi:10.1212/wnl.43.4.817 · Cited by 1,482
Pirart, J. (1978) · Diabetes Care · doi:10.2337/diacare.1.3.168 · Cited by 1,290
Hyperglycemic Pseudohypoxia and Diabetic Complications
Williamson, J. R., Chang, K., Frangos, M., Hasan, K. S., Ido, Y., Kawamura, T., Nyengaard, J. R., Den Enden, M. V., Kilo, C., & Tilton, R. G. (1993) · Diabetes · doi:10.2337/diab.42.6.801 · Cited by 1,105
Flier, J. S., Underhill, L. H., Greene, D. A., Lattimer, S. A., & Sima, A. A. F. (1987) · New England Journal of Medicine · doi:10.1056/nejm198703053161007 · Cited by 897
(2008) · PsycEXTRA Dataset · doi:10.1037/e549122009-001 · Cited by 862
Sima, A. A. F., Thomas, P. K., Ishii, D., & Vinik, A. (1997) · Diabetologia · doi:10.1007/bf03168192 · Cited by 822
Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy
Cameron, N. E., Eaton, S. E. M., Cotter, M. A., & Tesfaye, S. (2001) · Diabetologia · doi:10.1007/s001250100001 · Cited by 701
Yabe-Nishimura, C. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01347-4 · Cited by 526
Vinik, A. I., Park, T. S., Stansberry, K. B., & Pittenger, G. L. (2000) · Diabetologia · doi:10.1007/s001250051477 · Cited by 489
Diabetic Neuropathy: An intensive review
Duby, J. J., Campbell, R. K., Setter, S. M., White, J. R., & Rasmussen, K. A. (2004) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/61.2.160 · Cited by 382
Hotta, N., Akanuma, Y., Kawamori, R., Matsuoka, K., Oka, Y., Shichiri, M., Toyota, T., Nakashima, M., Yoshimura, I., Sakamoto, N., et al. (2006) · Diabetes Care · doi:10.2337/dc05-2370 · Cited by 366
McNeely, M. J., Boyko, E. J., Weigle, D. S., Shofer, J. B., Chessler, S. D., Leonnetti, D. L., & Fujimoto, W. Y. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.65 · Cited by 308
Report and Recommendations of the San Antonio Conference on Diabetic Neuropathy
American Diabetes Association, & American Academy of Neurology (1988) · Diabetes Care · doi:10.2337/diacare.11.7.592 · Cited by 286
Direct Measurement of Polyol Pathway Activity in the Ocular Lens
González, R. G., Barnett, P., Aguayo, J., Cheng, H.-M., & Chylack, L. T. (1984) · Diabetes · doi:10.2337/diab.33.2.196 · Cited by 165
Evaluation and prevention of diabetic neuropathy.
Aring, A. M., Jones, D. E., & Falko, J. M. (2005) · PubMed · Cited by 158
Heesom, A. E., Hibberd, M. L., Millward, A., et al. (1997) · Diabetes · doi:10.2337/diab.46.2.287 · Cited by 140
Aldose reductase structures: implications for mechanism and inhibition
El-Kabbani, O. A. L., Ruiz, F. M., Darmanin, C., & Chung, R. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3403-2 · Cited by 131
Endocrinology and Metabolism Clinics of North America
(2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(20)30021-9 · Cited by 117
Glucose utilization by the polyol pathway in human erythrocytes
Morrison, A. D., Clements, R. S., Travis, S. B., et al. (1970) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(70)91066-1 · Cited by 109
Diabetic Neuropathies: Features and Mechanisms
Zochodne, D. W. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00233.x · Cited by 100
Hamada, Y., Nakamura, J., Naruse, K., Komori, T., Kato, K., Kasuya, Y., Nagai, R., Horiuchi, S., & Hotta, N. (2000) · Diabetes Care · doi:10.2337/diacare.23.10.1539 · Cited by 93
Hotta, N., Sakamoto, N., Shigeta, Y., Kikkawa, R., & Gotō, Y. (1996) · Journal of Diabetes and its Complications · doi:10.1016/1056-8727(96)00113-4 · Cited by 92
Diabetic neuropathy: new strategies for treatment
Várkonyi, T. T., & Kempler, P. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00741.x · Cited by 86
Goto, Y., Hotta, N., Shigeta, Y., et al. (1995) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(96)82642-4 · Cited by 85
Steele, J., Faulds, D. M., & Goa, K. L. (1993) · Drugs & Aging · doi:10.2165/00002512-199303060-00007 · Cited by 84
Hotta, N., Kakuta, H., Fukasawa, H., Kimura, M., Koh, N., Iida, M., Terashima, H., Morimura, T., & Sakamoto, N. (1985) · Diabetologia · doi:10.1007/bf00273868 · Cited by 68
Aldose reductase inhibition in the treatment of diabetic neuropathy: Where are we in 2004?
Gabbay, K. H. (2004) · Current Diabetes Reports · doi:10.1007/s11892-004-0047-z · Cited by 54
Clinical Potential of Aldose Reductase Inhibitors in Diabetic Neuropathy
Hamada, Y., & Nakamura, J. (2004) · Treatments in Endocrinology · doi:10.2165/00024677-200403040-00006 · Cited by 50
Nakayama, M., Nakamura, J., Hamada, Y., Chaya, S., Mizubayashi, R., Yasuda, Y., Kamiya, H., Koh, N., & Hotta, N. (2001) · Diabetes Care · doi:10.2337/diacare.24.6.1093 · Cited by 47
Aldose reductase inhibition alters nodal Na + currents and nerve conduction in human diabetics
Misawa, S., Kuwabara, S., Kanai, K., Tamura, N., Nakata, M., Sawai, S., Yagui, K., & Hattori, T. (2006) · Neurology · doi:10.1212/01.wnl.0000216260.39452.bf · Cited by 34
Okayama, N., Omi, H., Okouchi, M., Imaeda, K., Kato, T., Akao, M., Imai, S., Shimizu, M., Fukutomi, T., & Itoh, M. (2002) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(02)00178-2 · Cited by 33
Gotō, Y., Hotta, N., Shigeta, Y., Sakamoto, N., Kito, S., Matsuoka, K., Takahashi, A., Kikkawa, R., & Sakuma, A. (1993) · Diabetic Medicine · doi:10.1111/j.1464-5491.1993.tb00197.x · Cited by 26
Cited by
González, P., Lozano, P., Ros, G., & Solano, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119352 · Cited by 777
Jackson, P. A., Widen, J. C., Harki, D. A., & Brummond, K. M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00788 · Cited by 588
Diabetic neuropathy: cellular mechanisms as therapeutic targets
Vincent, A. M., Callaghan, B. C., Smith, A. L., & Feldman, E. L. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.137 · Cited by 566
Aldose Reductase, Oxidative Stress, and Diabetic Mellitus
Tang, W. H., Martin, K. A., & Hwa, J. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00087 · Cited by 458
Pharmaceutical cocrystals: A review of preparations, physicochemical properties and applications
Guo, M., Sun, X., Chen, J., & Cai, T. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.030 · Cited by 386
Metadata
- Authors
- Ramirez, M. A., & Borja, N. L.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2008-05
- Volume
- 28
- Issue
- 5
- Pages
- 646-655
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2154789716
- Cited by
- 303
- References
- 32
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.